Two Chinese Biotechs Raise $104m To Challenge GSK’s Shingrix

fund raising
MAXVAX and Luzhu expected to roll out vaccines to challenge GSK's Shingrix inside and outside China • Source: Alamy

More from China

More from Focus On Asia